Emerging drugs for the treatment of hepatocellular carcinoma.

Walid S Ayoub, Patricia D Jones, Ju Dong Yang, Paul Martin

Expert opinion on emerging drugs 2022 Jun

filter terms:

Hepatocellular carcinoma (HCC) remains a leading cause of liver-related mortality. Cirrhosis of any etiology is the major risk factor although HCC can develop in its absence in patients with hepatitis B and increasingly in those with nonalcoholic fatty liver disease. When detected at an early stage, curative options include surgical resection, liver transplantation, and/or ablative therapies. Unfortunately, most cases of HCC are recognized at an advanced stage when options are limited and noncurative. However, new systemic therapies with tyrosine kinase inhibitors and immunotherapy have expanded therapeutic options in advanced HCC. Advances in systemic therapy have given patients with advanced HCC hope and prolonged their survival. We discuss recent data and ongoing research efforts to improve the treatment of hepatocellular carcinoma with discussion of current and upcoming systemic therapies combining agents of different classes. Systemic therapy for HCC is in evolution. The inclusion of immunotherapy to systemic therapy has revolutionized the field of HCC treatment. Identification of the appropriate combination and sequence of systemic therapy coupled with discovery of reliable HCC biomarkers will lead to improved survival and individualized HCC therapy.

Citation

Walid S Ayoub, Patricia D Jones, Ju Dong Yang, Paul Martin. Emerging drugs for the treatment of hepatocellular carcinoma. Expert opinion on emerging drugs. 2022 Jun;27(2):141-149